During the COVID-19 pandemic, we have become acutely aware of how precious time is and the potential repercussions of delays or inefficiencies.
COVID-19 is transforming our ways of thinking about the development, manufacture and delivery of critical medicines to patients around the world.
The scale and speed of the global vaccine research and development effort in response to COVID-19 is unprecedented.
As African nations begin to ease lockdown restrictions, health systems are bracing to prevent the novel coronavirus from spreading rapidly through their populations.
Antimicrobial resistance (AMR) is a global health challenge which can undermine standard treatments and procedures on which we have come to rely.
I was pleased to address the American Association of Pharmaceutical Scientists (AAPS) on May 12 during a webinar focused on the impact of the COVID-19 pandemic on the supply of quality medicines.
As the impact of the COVID-19 pandemic continues to unfold, each day brings to light new realizations of just how interconnected, and sometimes vulnerable, the global supply chain for medicines is.
To those in the pharmaceutical industry, USP may be both familiar and a little mysterious. We’re all aware that USP documentary and reference standards help ensure the quality of medicines in the United States and around the world.
This morning, USP published a proposal in the Pharmacopeial Forum (PF) on Biological Products Nomenclature.